Frontera Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of FT-003 for Diabetic Macular Edema (DME)
Boston, MA, November 25, 2024 – Frontera Therapeutics is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared its AAV gene therapy product, FT-003 Injection, for a Phase 2 clinical trial targeting Diabetic Macular Edema (DME). This milestone follows the FDA’s prior clearance for FT-003 to conduct a Phase 2 trial […]